Cyclo Therapeutics Inc. (NASDAQ: CYTH) Stock Information | RedChip

Cyclo Therapeutics Inc. (NASDAQ: CYTH)


$0.6010
-0.0290 ( +0.77% ) 19.8K

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Market Data


Open


$0.6010

Previous close


$0.6300

Volume


19.8K

Market cap


$17.45M

Day range


$0.6050 - $0.6200

52 week range


$0.5700 - $2.1150

SEC Filings


Form Type Description Pages Date
8-k 8K-related 16 Dec 23, 2024
10-k/a Quarterly Reports 92 Dec 18, 2024
8-k 8K-related 16 Dec 05, 2024
10-k/a Quarterly Reports 93 Nov 26, 2024
4 Insider transactions 1 Nov 18, 2024
4 Insider transactions 1 Nov 18, 2024
4 Insider transactions 1 Nov 18, 2024
4 Insider transactions 1 Nov 18, 2024
4 Insider transactions 1 Nov 18, 2024
4 Insider transactions 1 Nov 18, 2024

Latest News